« Back to Record
Citation APA

Lebbe, C., Dutriaux, C., Lesimple, T., Kruit, W. H., Kerger, J., Thomas, L., Guillot, B., De Braud, F. D., Garbe, C., Grob, J. J., Loquai, C., Ferraresi, V., Robert, C., Vasey, P., Conry, R., Isaacs, R., Espinosa, E., Schueler, A., Massimini, G., & Dreno, B. (2020). Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover. Cancers (Basel), 12(7), 1727, 1-11. doi:10.3390/cancers12071727


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/311520

Lebbe, C., Dutriaux, C., Lesimple, T., Kruit, W. H., Kerger, J., Thomas, L., Guillot, B., De Braud, F. D., Garbe, C., Grob, J. J., Loquai, C., Ferraresi, V., Robert, C., Vasey, P., Conry, R., Isaacs, R., Espinosa, E., Schueler, A., Massimini, G., & Dreno, B. (2020). Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover. Cancers (Basel), 12(7), 1727, 1-11. doi:10.3390/cancers12071727